Inhibition of the isoenzyme of glutaminyl cyclase that is responsible for cyclization of glutamine into pyroglutamic acid, coincided with reduction of CCL2-driven monocyte recruitment in vivo with beneficial effects on atherosclerosis progression (47). The gene discussed is CCL2; the disease is atherosclerosis.